Medifast’s (MED) Sell (D) Rating Reaffirmed at Weiss Ratings

Medifast (NYSE:MED)‘s stock had its “sell (d)” rating reissued by analysts at Weiss Ratings in a note issued to investors on Wednesday,Weiss Ratings reports.

Medifast Stock Up 1.0%

Shares of Medifast stock opened at $14.00 on Wednesday. The stock has a market capitalization of $153.87 million, a P/E ratio of 43.75 and a beta of 0.85. The stock has a 50 day moving average price of $13.77 and a two-hundred day moving average price of $13.58. Medifast has a 12-month low of $11.57 and a 12-month high of $21.98.

Medifast (NYSE:MED) last announced its quarterly earnings data on Monday, August 4th. The specialty retailer reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.22) by $0.26. The business had revenue of $105.56 million for the quarter, compared to the consensus estimate of $96.10 million. Medifast had a net margin of 0.76% and a return on equity of 2.00%. Medifast has set its Q3 2025 guidance at -0.600-0.00 EPS. Sell-side analysts anticipate that Medifast will post 0.51 earnings per share for the current year.

Institutional Investors Weigh In On Medifast

Hedge funds and other institutional investors have recently modified their holdings of the stock. GAMMA Investing LLC lifted its position in Medifast by 3,207.2% in the first quarter. GAMMA Investing LLC now owns 3,208 shares of the specialty retailer’s stock worth $43,000 after purchasing an additional 3,111 shares during the period. SummerHaven Investment Management LLC lifted its position in Medifast by 2.2% in the first quarter. SummerHaven Investment Management LLC now owns 42,073 shares of the specialty retailer’s stock worth $567,000 after purchasing an additional 916 shares during the period. Values First Advisors Inc. lifted its position in Medifast by 3.8% in the first quarter. Values First Advisors Inc. now owns 64,228 shares of the specialty retailer’s stock worth $869,000 after purchasing an additional 2,340 shares during the period. Peapod Lane Capital LLC bought a new position in Medifast in the first quarter worth $933,000. Finally, Charles Schwab Investment Management Inc. lifted its position in Medifast by 132.7% in the first quarter. Charles Schwab Investment Management Inc. now owns 265,572 shares of the specialty retailer’s stock worth $3,580,000 after purchasing an additional 151,434 shares during the period. Institutional investors and hedge funds own 95.51% of the company’s stock.

Medifast Company Profile

Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.